ITGAV and cancer: Further pan-cancer analyses demonstrated that ITGAV expression was related to the poor overall survival of patients with LGG, glioma, LIHC, mesothelioma, stomach adenocarcinoma, PAAD, stomach, and esophageal carcinoma, LUAD, and kidney renal papillary cell carcinoma; moreover, it was also associated with shorter disease-free survival of PAAD patients.